tafamidis - search results

United States - English - NLM (National Library of Medicine)

vyndaqel- tafamidis meglumine capsule, liquid filled vyndamax- tafamidis capsule, liquid filled

pfizer laboratories div pfizer inc - tafamidis meglumine (unii: zu7cf08a1a) (tafamidis - unii:8fg9h9d31j) - vyndaqel and vyndamax are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (attr-cm) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. none. risk summary based on findings from animal studies, vyndaqel and vyndamax may cause fetal harm when administered to a pregnant woman. however, limited available human data with vyndaqel use in pregnant women (at a dose of 20 mg per day) have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproductive studies, oral administration of tafamidis meglumine to pregnant rabbits during organogenesis resulted in adverse effects on development (embryofetal mortality, fetal body weight reduction and fetal malformation) at a dosage providing approximately 9 times the human exposure (auc) at the maximum recommended human dose (mrhd) of vyndaqel (80 mg), and increased incidence of fetal skeletal variation at a dosage providing equivalent human exposure (auc) at the mrhd. postnatal mortality, growth retardation, and impaired learning and memory were observed in offspring of pregnant rats administered tafamidis meglumine during gestation and lactation at a dosage approximately 2 times the mrhd based on body surface area (mg/m2 ) (see data) . advise pregnant women of the potential risk to a fetus. report pregnancies to the pfizer reporting line at 1-800-438-1985. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data in pregnant rats, oral administration of tafamidis meglumine (0, 15, 30, and 45 mg/kg/day) throughout organogenesis resulted in decreased fetal body weights at ≥30 mg/kg/day (approximately 10 times the human exposure at the mrhd based on auc). the no-observed-adverse-effect-level (noael) for embryofetal development in rats was 15 mg/kg/day (approximately 7 times the human exposure at the mrhd based on auc). in pregnant rabbits, oral administration of tafamidis meglumine (0, 0.5, 2, and 8 mg/kg/day) throughout organogenesis resulted in increased embryofetal mortality, reduced fetal body weights, and an increased incidence of fetal malformations at 8 mg/kg/day (approximately 9 times the human exposure at the mrhd based on auc), which was also maternally toxic. increased incidences of fetal skeletal variations were observed at doses ≥0.5 mg/kg/day (approximately equivalent to the human exposure at the mrhd based on auc). in the pre- and postnatal study, pregnant rats received oral administration of tafamidis meglumine at doses of 0, 5, 15, or 30 mg/kg/day throughout pregnancy and lactation (gestation day 7 to lactation day 20). decreased survival and body weights, delayed male sexual maturation and neurobehavioral effects (learning and memory impairment) were observed in the offspring of dams treated at 15 mg/kg/day (approximately 2 times the mrhd on a mg/m2 basis). the noael for pre- and postnatal development in rats was 5 mg/kg/day (approximately equivalent to the mrhd on a mg/m2 basis). risk summary there are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. tafamidis is present in rat milk (see data) . when a drug is present in animal milk, it is likely the drug will be present in human milk. based on findings from animal studies which suggest the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with vyndaqel or vyndamax. data pregnant and lactating female rats were administered repeated daily oral doses of tafamidis meglumine (15 mg/kg/day) followed by a single oral gavage dose of 14 c-tafamidis meglumine on lactation day 4 or 12. radioactivity was observed in milk by 1 hour post-dose and increased thereafter. the ratio of the highest radioactivity associated with 14 c tafamidis meglumine in milk (8 hours post-dose) vs. plasma (1 hour post-dose) was approximately 1.6 on day 12, indicating tafamidis meglumine is transferred to milk after oral administration. contraception females based on findings from animal studies, vyndaqel and vyndamax may cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . consider pregnancy planning and prevention for females of reproductive potential. the safety and effectiveness of vyndaqel and vyndamax have not been established in pediatric patients. no dosage adjustment is required for elderly patients (≥65 years) [see clinical pharmacology (12.3)] . of the total number of patients in the clinical study (n=441), 90.5% were 65 and over, with a median age of 75 years.

Israel - English - Ministry of Health

vyndamax

pfizer pharmaceuticals israel ltd - tafamidis - capsules soft gelatin - tafamidis 61 mg - tafamidis - vyndamax is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Israel - English - Ministry of Health

vyndaqel

pfizer pharmaceuticals israel ltd - tafamidis as meglumine - capsules soft gelatin - tafamidis as meglumine 12.2 mg - tafamidis - for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

European Union - English - EMA (European Medicines Agency)

vyndaqel

pfizer europe ma eeig - tafamidis - amyloidosis - other nervous system drugs - vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.